Researchers evaluate the efficacy of plazosiran treatment on fasting triglyceride levels in adult patients with mixed hyperlipidemia.
By Dr. Liji Thomas, MDMay 31 2024Reviewed by Benedette Cuffari, M.Sc. In a recent study published in The New England Journal of Medicine , researchers evaluate the efficacy of plazosiran treatment on fasting triglyceride levels in adult patients with mixed hyperlipidemia .
Like LDL cholesterol, remnant cholesterol from triglyceride-rich lipoproteins contribute to plaque formation. Although current LDL cholesterol-lowering agents can successfully reduce the risk of CHD in MH, they do not reduce triglyceride or remnant cholesterol levels. Related StoriesOne potential drug that could downregulate APOC3 is plazosiran, which is a small interfering ribonucleic acid agent that targets APOC3 within hepatocytes. Plazosiran has been shown to be highly specific and potent with limited associated side effects.
About 92% of patients were currently receiving statins, 54% of whom were receiving high-intensity statins. Other cholesterol-lowering agents were used by 2-14% of participants.
RNA RNA Interference Apolipoprotein Atherosclerosis Blood Blood Pressure Blood Sugar Calcium Cardiovascular Disease Cholesterol Chylomicron Coronary Heart Disease Drugs Efficacy Fasting Fatty Acids Heart Heart Disease Lipoprotein Liver Medicine Peripheral Arterial Disease Placebo Stroke Triglyceride
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
RNAConnect, Inc. formally launches today to drive RNA analysis with innovative research toolsRNAConnect, a pioneering life science reagent company, officially launches today, promising groundbreaking solutions for exploring the real-world diversity of RNA sequence and structure.
Read more »
Advanced characterization of RNA-ligand binding dynamics through MMS technologyThis article explores the use of MMS technology for characterization of RNA-ligand binding dynamics.
Read more »
Advancing cancer therapeutics: Development of assays for measuring RNA helicase activityThis article explores advancing cancer therapeutics and the development of selective RNA helicase inhibitors.
Read more »
Study uncovers molecular mechanism linking nonsense-mediated RNA decay to microcephalyNonsense-mediated RNA decay, or NMD, is an evolutionarily conserved molecular mechanism in which potentially defective messenger RNAs, or mRNAs (genetic material that instructs the body on how to make proteins), are degraded.
Read more »
Drug targeting RNA modifications shows promise for treating neuroblastomaNeuroblastoma is a common pediatric cancer that originates in developing nerve cells outside the brain. While increasingly intensive treatments have improved the survival of patients with high-risk neuroblastoma, currently more than 40% of patients do not survive.
Read more »
Study finds that the transport of mRNAs into axons along with lysosomal vesicles prevents axon degenerationRNA granules, sites for the storage, transport, and regulation of RNA molecules within cells, are transported along axons and then translated locally, far from the cell body.
Read more »